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Aims Clinical practice guidelines do not recommend discontinuation of long-term oral anticoagulation in patients with a
high stroke risk after catheter ablation for atrial fibrillation (AF). Left atrial appendage closure (LAAC) with
Watchman has emerged as an alternative to long-term anticoagulation for patients accepting of the procedural
risks. We report on the long-term outcomes of combining catheter ablation procedures for AF and LAAC from
multicentre registries.
...................................................................................................................................................................................................
Methods
and results
Data were pooled from two prospective, real-world Watchman LAAC registries running in parallel in Europe/
Middle-East/Russia (EWOLUTION) and Asia/Australia (WASP) between 2013 and 2015. Of the 1140 patients, 142
subjects at 11 centres underwent a concomitant AF ablation and LAAC procedure. The mean CHA2DS2-VASc
score was 3.4 ± 1.4 and HAS-BLED score 1.5 ± 0.9. Successful LAAC was achieved in 99.3% of patients. The 30-day
device and/or procedure-related serious adverse event rate was 2.1%. After a mean follow-up time of
726 ± 91 days, 92% of patients remained off oral anticoagulation. The rates of the composite endpoint of ischaemic
stroke/transient ischaemic attack/systemic thromboembolism were 1.09 per 100 patient-years (100-PY); and for
non-procedural major bleeding were 1.09 per 100-PY. These represent relative reductions of 84% and 70% vs.
expected rates per risk scores.
...................................................................................................................................................................................................
Conclusion The long-term outcomes from these international, multicentre registries show efficacy for all-cause stroke preven-
tion and a significant reduction in late bleeding events in a population of high stroke risk post-ablation patients who
have been withdrawn from oral anticoagulation.
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Introduction
No randomized controlled trials to date have shown a reduction in
the risk of thromboembolic events or ischaemic stroke following
catheter ablation therapy for atrial fibrillation (AF) as compared with
standard medical therapy and oral anticoagulation.1 The CHA2DS2-
VASc risk score has been shown to correlate with both risk of AF re-
currence and risk of thromboembolic events post-ablation,2 and
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underscores the need for on-going stroke protection in high-risk
patients. Accordingly, clinical practice guidelines recommend contin-
uation of long-term oral anticoagulation in high stroke risk patients
following catheter ablation therapy.3
Catheter-based left atrial appendage (LAA) occlusion, in contrast,
has demonstrated efficacy for all-cause stroke prevention in non-
valvular AF and can provide a mechanical alternative to long-term
anticoagulation.4 It has been suggested that combining the two left
atrial interventions may be a valuable and practical approach.5 We re-
port on the 2-year outcomes of combined catheter ablation proce-
dures for AF with LAA closure as studied in prospective international
multicentre registries.
Methods
The study design has previously been described in detail in the first report
on peri-procedural outcomes.6 Subgroup analysis was planned prospec-
tively for patients undergoing concomitant catheter ablation of AF with
Watchman (Boston Scientific Corporation; Natick, MA, USA) left atrial
appendage closure (LAAC) during participation in either the
EWOLUTION or WASP registries. The EWOLUTION and WASP reg-
istries were designed to collect real-world usage and outcomes data for
patients implanted with the Watchman LAA closure device and were
registered on ClinicalTrials.gov (NCT01972282 and NCT01972295, re-
spectively).7,8 Both registries used appropriate guidelines to determine
device eligibility and were performed by trained implanters. The study
was approved by the respective institutional review boards for human re-
search and complies with the Declaration of Helsinki. Informed consent
was obtained from all participants. A contract research organization mon-
itored both studies and conducted multiple site visits to verify the accu-
racy and completeness of follow-up data.
Procedure
Catheter ablation for AF was performed per physician discretion with the
choice of ablation energy modality, ancillary catheters, and use of cardiac
navigational system individualized to patients and physician preferences.
The ablation endpoint was left and right-sided pulmonary vein electrical
isolation, as well as any additional left or right atrial ablation, deemed nec-
essary by the operator. After completion of the ablation phase, the trans-
septal sheath was exchanged for the Watchman access sheath. One
centre reported using intracardiac echocardiography during the ablation
phase of the procedure, however, all centres reported use of transoeso-
phageal echocardiography (TOE) to guide LAA device closure. Implant of
the LAA closure device was then performed as previously described.7,8
Peri-procedural oral anticoagulation (OAC), intravenous heparin, and
target-activated clotting time were managed at the physician’s discretion.
Patient follow-up
The schedule of clinical follow-up was at the discretion of the physician
and according to each institution’s standard practice. Generally, clinical
review was performed at 2–3 months post-procedure and then annually
thereafter. Additional telephone contact was made with patients during
the study.
Follow-up TOE imaging was recommended at 6 weeks to reassess de-
vice position and any residual jet flow around the device. Left atrial ap-
pendage occlusion was defined as satisfactory positioning of the device at
the ostium covering all trabeculated portions of the LAA with peri-device
flow <_5 mm.4 If satisfactory appearances on TOE follow-up study had
been confirmed, anticoagulation discontinuation was recommended at
the next follow-up visit and patients were then recommended for antipla-
telet therapy (aspirin 81  325 mg þ clopidogrel 75 mg) for 6 months
post-implant or at the discretion of the physician.
Data collection and event definition
All data collection and adverse event reporting were performed directly
by the individual sites and captured in a standardized central database. All
centres were monitored by an outside contract research organization on
an ongoing basis with one or more site visits depending on the number of
patients enrolled and compliance review.
Both trials required serious adverse events (SAEs) reporting per ISO
14155 and the MEDDEV 2.7/3 12/2010. Adjudication was performed by
investigators with oversight by a Medical Safety Group. Events included
procedure-related complications (e.g. serious pericardial effusion, device
embolization, and procedure-related stroke) and events related to exces-
sive bleeding (e.g. intracranial or gastrointestinal bleeding) scored accord-
ing to the Bleeding Academic Research Consortium (BARC) criteria. The
definition of various safety events and major bleeding align with reporting
standards suggested by the consensus document.9 Safety events were fur-
ther classified as Watchman procedure–related, device-related or related
to prescribed anticoagulation regimen.
Screening for recurrent atrial tachyarrhythmias and follow-up of
rhythm outcomes was left to the physician’s discretion. Data were not
collected on rhythm outcomes in the central databases and is not
reported on as part of these studies.
Endpoints
Efficacy endpoints required reporting of any occurrence of stroke (includ-
ing ischaemic or haemorrhagic stroke), death, or systemic embolism (SE).
The primary endpoints of this study were efficacy of the procedure and
device to prevent the combined endpoint of stroke, transient ischaemic
attack (TIA), or SE over 2-year follow-up. Secondary endpoints included
assessment of procedural success and safety, assessment of bleeding
events, and all-cause mortality over 2-year follow-up.
Statistical analysis
Continuous variables are summarized using the mean, standard deviation,
range, and categorical variables with counts and percentages. Predicted
risk of annual stroke (in the absence of therapy) and bleeding (during anti-
coagulant therapy) was extrapolated for each individual subject based on
CHA2DS2-VASc and HAS-BLED scores using published literature
10,11
and then the average risk for the study population was used to determine
the expected rates for comparison to observed rates and risk reduction
What’s new?
• This study reports on long-term outcomes from a subset of
patients who underwent combined catheter ablation for atrial
fibrillation and left atrial appendage closure procedures while
enrolled in the large real-world WASP and EWOLUTION
Watchman Registries.
• The results provide further multicentre evidence that the com-
bined procedure provides efficacious long-term stroke preven-
tion as well as reduced risk of major bleeding by allowing
high-risk post-ablation patients to safely stop oral
anticoagulation.
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calculations. Rates of stroke, TIA, SE, death, and bleeding events are cal-
culated as number of events per 100 patient-years (100-PY) and esti-
mates of rates and 95% confidence intervals for each subgroup are
derived from a Poisson Model. The Kaplan–Meier method was used to
describe SAE rates at specific time points in follow-up. The Fisher’s exact
test was used to compare binomial proportions, and t-test to compare
continuous variables.
Results
Patient demographics
Enrolment in the EWOLUTION study included 1025 patients and
spanned from October 2013 to May 2015 in 47 centres across 13
countries in Europe, the Middle East, and Russia. Enrolment in the
WASP trial commenced in January 2014 and concluded in October
2015, resulting in 201 patients across seven countries including
Australia, Asia, and the Middle East.
Of the 1140 patients from both registries, 142 subjects at 11
centres underwent a concomitant ablation and LAAC procedure and
are included in the analysis. The majority of cases (97%) were per-
formed by experienced AF catheter ablation proceduralists (>_50
procedures per year). The results have previously been published in
part as an initial report on 30-day procedural outcomes.6 Subsequent
to the initial publication site monitoring visits revealed three addi-
tional patients who had undergone concomitant catheter ablation
procedures for AF but had been initially incorrectly classified in the
database.
The mean age at time of consent was 64.2 ± 7.2 years (range 39–
85), and 54.2% of patients were male. Stroke risk scores (mean ±
standard deviation) for CHADS2 and CHA2DS2-VASc were 2.2± 1.2
and 3.4 ± 1.4, respectively, while the HAS-BLED score was 1.5 ± 0.9.
The primary AF pattern was paroxysmal in 69%. A prior history of
ischaemic stroke or TIA was recorded in 40.1% of patients, conges-
tive heart failure in 33.8%, and left ventricular systolic dysfunction
[left ventricular ejection fraction (LVEF) <_40%] in 2.1%. The indica-
tions for LAA device occlusion included labile international normal-
ized ratios (INRs) in 25 (17.6%), requirement for concomitant drug
therapy in 45 (31.7%), previous major bleeding in 14 (9.9%), recur-
rent anaemia due to gastrointestinal bleeding in 4 (2.8%), history of
blood dyscrasia in 1 (0.7%), history of haemorrhagic tendency in 5
(3.5%), alcohol abuse in 8 (5.6%), senility in 1 (0.7%), job or lifestyle
that prohibits warfarin use in 28 (19.7%), other contraindication, e.g.
HAS-BLED score >_3 in 20 (14.1%), and reason not recorded in 29
(20.4%). For a complete listing of all demographics, see Table 1.
Procedural characteristics and success
The ablation modality used by the different operators included irri-
gated radiofrequency ablation in 106 patients, cryoballoon in one pa-
tient, non-irrigated phased radiofrequency multielectrode
applications in 30 patients and modality not recorded in five patients.
Ablation endpoints were not recorded in the registry dataset.
Successful LAAC was achieved in 141/142 (99.3%) with one implant
abandoned following the ablation phase of the procedure after rec-
ognition of a serious pericardial effusion which required pericardio-
centesis. All implants achieved a satisfactory seal (residual leak <5
mm) per device release specifications4 with 137/141 (97.2%)
achieving a complete seal and 4/141 (2.8%) accepting a small peri-
device leak. The mean LAA diameter was 20.8± 2.8 mm (range 14–
28), resulting in final median device size of 24 mm.
Oral anticoagulant regimen
Post-procedure, 92.9% of patients were prescribed an oral anticoagu-
lant [54.2% non-vitamin K antagonist oral anticoagulants (NOAC),
.................................................................................................
Table 1 Baseline characteristics
Characteristics Summary
statistics
Age at time of consent (years)
Mean ± SD 64.2 ± 7.2
Range 39.0–85.0
Age >_80 0.7% (1/42)
Male 54.2% (77/142)
CHADS2 score—continuous
Mean ± SD 2.2 ± 1.2
Range 0.00–5.00
CHA2DS2-VASc score—continuous
Mean ± SD 3.4 ± 1.4
Range 0.00–7.00
HAS-BLED score—continuous
Mean± SD 1.5 ± 0.9
Range (0.00, 4.00)
Components of CHADS2 and CHA2DS2-VASc scores
CHF 33.8% (48/142)
Hypertension 80.3% (114/142)
Age >_75 9.2% (13/142)
Age 65–74 42.3% (60/142)
Diabetes 13.4% (19/142)
History of TIA/Stroke 40.1% (57/142)
Vascular disease 20.4% (29/142)
Female 45.8% (65/142)
Components of HAS-BLED scores
Uncontrolled hypertension 15.5% (22/142)
Abnormal renal function 2.1% (3/142)
Abnormal liver function 0.7% (1/142)
History of ischaemic/haemorrhagic stroke 28.9% (41/142)
Prior major bleeding or predisposition
to bleeding
4.9% (7/142)
Labile INRs 17.6% (25/142)
Concomitant use of drugs 31.7% (45/142)
Alcohol abuse 5.6% (8/142)
Age >65 41.5% (59/142)
AF pattern
Paroxysmal 69.0% (98/142)
Persistent 28.9% (41/142)
Long-standing persistent 1.4% (2/142)
Values presented are % (N/total) or mean ± standard deviation, range (mini-
mum–maximum).
AF, atrial fibrillation; CHF, congestive heart failure; INRs, international normalized
ratios; SD, standard deviation; TIA, transient ischaemic attack.
Combining LAA closure and catheter ablation for AF 227
D
ow
nloaded from
 https://academ
ic.oup.com
/europace/article-abstract/22/2/225/5610173 by Erasm
us U
niversiteit R
otterdam
 user on 19 February 2020
38.7% warfarin], 5.6% were given anti-platelet (3.5% dual, 2.1% sin-
gle), and the remainder received no therapy (1.4%).
Peri-procedural safety
The 7-day device and/or procedure-related SAE rate was 1.4% (0.3–
4.5%). The 30-day device and/or procedure-related SAE rate was
2.1% (0.6–5.6%). There were two serious pericardial effusions requir-
ing pericardiocentesis (1.4%): one pericardial effusion was identified
during the procedure following the ablation phase (therapeutic INR
of 2.6 on warfarin) and required percutaneous drainage with un-
eventful recovery (but caused LAAC implant to be abandoned),
while a second pericardial effusion with tamponade occurred on Day
12 post-procedure and was resolved with pericardiocentesis. There
were four significant bleeding events within the first 30 days as previ-
ously described7 including gastrointestinal bleeding on NOAC Day 1,
frank haematuria on warfarin Day 5, secondary bleed from groin (vas-
cular access) on warfarin on Day 13, and traumatic knee haematoma
on NOAC on Day 28 post-procedure. The bleeding SAE rate at 30
days was 2.8% (0.9–6.6%). There were no peri-procedural strokes/
TIAs, device embolization or deaths.
Transoesophageal echocardiography
follow-up
A first follow-up TOE in patients with a successful implant was per-
formed at least 28 days post-procedure in 109/141 (77%) patients.
Satisfactory LAA occlusion was noted in 107/109 (98.2%). Two
patients had a jet size >5 mm determined to be due to device migra-
tion and were continued on OAC for the duration of the study due
to unsuccessful LAA closure. Device-related thrombus (DRT) was
detected during early follow-up TOE in three patients (2.1%) while
still on OAC (Days 38, 45, and 45). There was no history of reduced
LVEF or congestive cardiac failure in patients who developed DRT
and all patients were identified to have appropriate positioning of the
device (without malrotation) and with complete LAA seal. One pa-
tient had a history of paroxysmal AF and two patients had persistent
AF prior to the index procedure with CHA2DS2-VASc scores ranging
between 2 and 3. The rhythm at the time the thrombus was detected
was sinus in two and unrecorded in one patient. Sessile thrombus
across the atrial facing surface of the device was noted in one and
mobile, pedunculated thrombus was attached to the inferior margin
of the device in one, with no data available on the third patient. All
patients were taking NOACs at the time of diagnosis which were
continued until documented thrombus resolution (4 weeks to
4 months timeframe). All DRT patients were then successfully with-
drawn from OAC. Device embolization was detected in one patient
on Day 43 as part of investigations for difficulty walking. Radiological
assessment detected the device at the distal bifurcation of the aorta.
The device was retrieved surgically without complications.
Antithrombotic therapy at follow-up
Subsequent to the first follow-up visit 132/141 (94%) of implanted
patients were discontinued from or taking no oral anticoagulant. At
2-year follow-up the following rates of therapy were recorded in
implanted patients: 8.0% OAC, 81.9% antiplatelet therapy (1.5% dual
and 80.4% single), and 10.1% on no therapy (Figure 1).
Long-term follow-up
The mean follow-up time for the cohort who were successfully
implanted was 726 ± 91 days (range 77–902). No patients were lost
to follow-up. Two patients underwent cardiac surgery during which
the surgeon chose to remove the LAA occlusion device and oversew
the LAA in the absence of any documented adverse events related to
the device. A total of five patients had bleeding events during
24 months of follow-up with four events clustered within the first
30 days and only one further event (gastrointestinal bleeding from
acute diverticulitis while on Aspirin) at Day 199. The observed
total major bleeding event rate was 1.83 per 100-PY; however, the
non-procedural major bleeding rate was 1.09 per 100-PY. The
expected rate of spontaneous major bleeding as predicted by
HAS-BLED score if taking warfarin is 3.67 per 100-PY.11 This repre-
sents a 70% relative risk reduction for non-procedural bleeding
events (Figure 2).
One ischaemic stroke and five TIAs occurred in three patients dur-
ing follow-up. One patient experienced a TIA Day 15 post-
procedure on warfarin and aspirin therapy and was subsequently
changed to warfarin and clopidogrel which was then prescribed long
term. This patient was also identified to have device migration result-
ing in a peri-device leak of 5 mm on follow-up TOE and continued on
OAC due to incomplete LAA closure. The same patient went on to
suffer an ischaemic stroke on Day 458, and another TIA at day 610
(while still on warfarin and clopidogrel). Two patients experienced
three TIAs: one patient at Day 246 on clopidogrel (and was changed
to NOAC), a second patient at Day 262 while on warfarin (antiplate-
let therapy added), and also on Day 707. The latter patient had a
prior history of multiple TIA and strokes, and although had been ini-
tially withdrawn from OAC and changed to clopidogrel in early
follow-up, he was subsequently recommenced on warfarin by the
Neurologist when recurrent AF was detected 11 months post-
procedure. There was no evidence for device thrombus in any of the
patients who suffered TIA or stroke events. There was no correlation
between cases of early detected device thrombus and later stroke/
TIA events in the current study. There were no haemorrhagic
strokes or intracranial bleeding events.
The expected rate of ischaemic stroke predicted by mean
CHA2DS2-VASc score of 3.4 without oral anticoagulation (and as-
suming aspirin use) is 4.86 per 100-PY,10 however, the observed rate
.................................................................................................
Table 2 Endpoint event rates
Events Rate per 100
patients-years
95% CI
Death 0.36 0.05–2.53
Ischaemic stroke SAE 0.36 0.05–2.54
Ischaemic stroke/TIA/SE SAE 1.09 0.35–3.37
Major bleeding SAE 1.83 0.76–4.40
Non-procedure or device-related
major bleeding SAE
1.09 0.35–3.38
SAE, serious adverse event; SE, systemic embolism; TIA, transient ischaemic
attack.
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for the study was 0.36 per 100-PY (Table 2). This represents a 93%
relative risk reduction for stroke. When TIA and SE are added to the
combined endpoint the predicted event rate is 6.81 per 100-PY,10
with an observed rate for the study of 1.09 per 100-PY which trans-
lates to 84% relative risk reduction for stroke/TIA/SE (Figure 3).
There was one death over the follow-up period (patient found de-
ceased in bathtub at day 104—cause of death unclear) resulting in a
mortality event rate of 0.36 per 100-PY.
Discussion
The current study provides long-term registry outcomes for a multi-
national cohort of patients with AF and high stroke risk who have un-
dergone combined interventions of catheter ablation and LAAC. The
study provides important observational data that points to significant
lowering of expected stroke event rate despite 92% of patients dis-
continuing anticoagulation over the longer term. The results also
show low rates of bleeding at long-term follow-up, again significantly
lower than expected if the patient group had been consistently
prescribed anticoagulation. Further the results show good peri-
procedural safety for high-volume ablation operators with proce-
dural complication rates similar to those reported for catheter abla-
tion therapy alone.12 The results are consistent with two other
multicentre reports of mid to long-term outcomes following com-
bined ablation and LAAC procedures.13,14 A multinational registry
which followed up 349 patients with average CHA2DS2-VASc score
of 3.0 for a mean of 35 months off OAC documented an annualized
stroke rate of 0.9% for the cohort (78% risk reduction vs expected)
0.13 A Chinese multicentre registry documented one ischaemic
stroke during mean follow-up time of 20 months for a cohort of 50
patients off OAC with mean CHA2DS2-VASc score of 3.7.
14 These
long-term outcomes further support the acknowledgment that the
combined procedure can be described as a ‘valuable and practical ap-
proach’ as stated in the 2015 EHRA/EAPCI expert consensus state-
ment on catheter-based LAA occlusion.5
The ESC Guidelines for Management of Atrial Fibrillation ac-
knowledge that several observational studies have suggested a rela-
tively low stroke rate in the first few years after catheter ablation
of AF, but emphasize that the long-term risk of recurrent AF in
ablated patients need to be considered.3 While the guidelines con-
tinue to recommend anticoagulation after ablation based on stroke
risk scores rather than rhythm outcome3 the potential for serious
bleeding events in post-ablation patients subjected to long-term
anticoagulation has been raised by observational studies such as
the Danish National Registry.15 In the latter study, the incident
rates of ischaemic stroke were demonstrated to be higher in the
group who discontinued OAC than for those post-ablation
patients who remained anticoagulated over the median follow-up
time of 3.4 years, but the serious bleeding risks of OAC were sug-
gested to ‘outweigh’ the potential small benefits of stroke risk re-
duction.15 While the authors acknowledge that some degree of
reduction in stroke risk over the current study timeframe is likely
to have been conferred by catheter ablation the concomitant
LAAC strategy has provided a proven long-term stroke prevention
strategy that is equivalent to oral anticoagulation4 but with re-
moval of serious bleeding risks and without the ongoing require-
ment to carefully monitor for recurrent AF.
Global rates of catheter ablation treatment for AF have increased
significantly over the last two decades.16 Despite well-documented
improvements in symptoms and quality of life scores catheter abla-
tion has demonstrated few improvements in ‘hard endpoints’ in ran-
domized trials with only the subset of patients with left ventricular
systolic dysfunction and congestive cardiac failure showing reductions
in mortality.17 No randomized controlled trial of catheter ablation
for AF to date has shown a reduction in long-term thromboembolic
events or ischaemic stroke.1 In contrast, the Watchman LAAC pro-
cedure is a catheter-based treatment which has been demonstrated
in randomized controlled trials to reduce all-cause stroke and offers
improved cardiovascular mortality when compared with warfarin
anticoagulation.4 The combination of LAAC (a proven stroke pre-
vention therapy) with catheter ablation could thereby offer prognos-
tically important outcomes from a single intervention. Further, the
prognostic benefit from a ‘bolt-on’ LAAC intervention is likely to be
widely applicable due to the prevalence of high stroke risk in the AF
population seeking catheter ablation. While the usual decision-
making process to arrive at LAAC procedure involves careful
None DAPT
Prescribed OAC or antiplatelet
OAC
100.0%
80.0%
60.0%
40.0%
20.0%
1.5%
80.4%
Antithrombotic treatment at end of 2 year follow-up
10.1%
8.0%
0.0%
Single APT
Figure 1 Anticoagulation drugs used by subjects at end of 2-year follow-up period. Single APT, single-antiplatelet therapy; DAPT, dual-antiplatelet
therapy; OAC, oral anticoagulant (NOAC or warfarin).
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consideration of procedural risks as compared with other long-term
risks of continuing anticoagulation or the risks of no prophylaxis,
patients undergoing catheter ablation for AF have already accepted
procedural risk.
For patients with a high stroke risk who are already undertaking
the procedural risks of catheter ablation a ‘bolt-on’ stroke prevention
therapy with LAAC could represent a shift in the care paradigm. If
the opportunistic LAAC can be performed at minimal extra cost/risk,
the long-term benefits of mechanical stroke prevention (with en-
sured compliance) and reduction in bleeding events from discontinu-
ation of oral anticoagulation may be considerable.
Effect on long-term bleeding
The low rate of long-term (non-procedural) bleeding in the current
study is notable and is likely explained by 92% of the cohort being
discontinued from oral anticoagulation. Long-term therapy with a
novel anticoagulant confers an annual major bleeding risk of 2.13–
3.6% in contemporary trials.18 A link between spontaneous bleeding
events and a significant increase in mortality has been demonstrated
in multiple trials of patients with coronary artery disease.19 Although
the populations are not directly comparable, it may be important to
understand the impact of spontaneous major bleeding events on
prognosis/mortality in an aging population who are prescribed long-
term OAC. PROTECT-AF and the wider meta-analysis of
Watchman studies have already demonstrated a clinically and statisti-
cally significant reduction in cardiovascular mortality of Watchman
LAAC over long-term warfarin anticoagulation4 and it is intriguing to
postulate whether this may be cumulative benefit from reduced ma-
jor bleeding events in an aging cohort.
Study limitations and future directions
Because these registries were designed as LAAC outcome studies,
the datasets did not include arrhythmia outcomes and the authors ac-
knowledge this as a limitation. There is no proof as yet that catheter
ablation modifies the risk of thromboembolic stroke in high-risk
patients with AF,1,20 and long-term follow-up studies following cathe-
ter ablation have generally shown progressive arrhythmia recurrence,
especially for patients with non-paroxysmal AF.20 Accordingly
Wintgens et al.13 multicentre pooled registry experience of com-
bined ablation and Watchman LAAC showed AF recurrence in 51%
of patients by 35 months follow-up and similarly in the Chinese multi-
centre registry AF recurred at a rate of 36% by 20 months mean fol-
low-up.14
Whether the concomitant LAAC procedure detrimentally affects
the rhythm outcomes from ablation also cannot be answered by the
current study. Larger randomized trials such as the currently enroll-
ing OPTION study (NCT03795298) will be needed to assess for dif-
ferences between performing the procedures separately vs. a
combined approach and to specifically address any interaction with
different ablation modalities.
Although registry data provides a beneficial real-world practice
perspective, it does lead to variability in peri-procedural management
(e.g. variation in ablation modality, anticoagulation regimen) and non-
conformity of follow-up. Prospective collection of data into a central
database with multiple monitoring visits has, however, enabled rigor-
ous documentation of these variations.
The authors also acknowledge that the predictive accuracy of
CHA2DS2-VASc and HAS-BLED scores for estimating expected
stroke and bleeding rates in a post-catheter ablation cohort is un-
known. The potential for overestimation of LAAC effect on stroke
event rates, in particular, is considered likely.
The authors acknowledge that regulatory and reimbursement con-
siderations in different regions around the world will have an impact
on the ease with which physicians might adopt the combined
approach.
Conclusions
The outcomes from these international, multicentre registries sup-
port long-term safety and efficacy of a combined ablation and LAAC
procedure for all-cause stroke prevention and a significant reduction
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Figure 2 Calculated major bleeding risk based on HAS-BLED
score, actual observed major bleeding rates and relative risk reduc-
tion (left), and observed major bleeding rate excluding procedural
bleeding and relative risk reduction (right) after 2-year follow-up.
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Figure 3 Calculated stroke risk based on CHA2DS2-VASc score,
actual observed stroke rate and the relative risk reduction (left),
and calculated stroke/TIA/SE risk based on CHA2DS2-VASc score,
actual observed combined endpoint of stroke/TIA/SE rate and the
relative risk reduction (right) after 2-year follow-up. TIA, transient
ischaemic attack; SE, systemic embolism. Effectiveness in stroke re-
duction vs. estimated in the absence of therapy for comparable
CHA2DS2-VASc scores based on Friberg et al.
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in late bleeding events in a population of high stroke risk post-
ablation patients who have been withdrawn from long-term oral
anticoagulation.
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